Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 9 Issue 5, November 2015

Volume 9 Issue 5

In this issue...

• Dermatology: Three major indications propel partnering

• Regulatory red carpet rolls out for antibiotic developers

• Next-generation antibody platforms take off

Cover image: Virus, cells. Ugreen / Getty Images

Dermatology partnering

    Feature

  • News Feature |

    The dermatology space is emerging from an active period of diversification and consolidation that has opened up new partnering opportunities. Besides the cosmetic market, the medical segment has also entered a growth phase propelled by three indications: melanoma, psoriasis and systemic lupus erythematosus.

    • Gaspar Taroncher-Oldenburg
  • Profiles

  • Advertisement Feature |

    With OC459, a first-in-class, oral, once-a-day small molecule for atopic dermatitis, Atopix has a potential winner for this and other type 2 helper T cell–mediated disorders such as severe asthma and related allergic conditions.

  • Advertisement Feature |

    LEO Pharma is focusing on improving outcomes for those living with skin diseases and is seeking new strategic partnerships to change the treatment paradigm in dermatology.

  • Advertisement Feature |

    DermTech’s adhesive patch platform enables non-invasive gene expression analysis.

Antibiotic dealmaking

    Feature

  • News Feature |

    A commercial environment reinvigorated by improved fundamentals—increased regulatory flexibility and the emergence of exciting new scientific opportunities and innovative business models—has set the stage for a resurgence in the antibiotics space that has already led to an uptick in early-stage venture investment and strategic partnerships.

    • Suzanne Elvidge
  • Profiles

  • Advertisement Feature |

    Helperby’s antibiotic-resistance breakers are a powerful tool serving to prolong and boost antibiotic efficacy and should help counter the growing global crisis of antibiotic resistance.

    • Helperby Therapeutics Ltd
  • Advertisement Feature |

    The London-based translational research company is pioneering the development of innovative imaging biomarkers to enhance efficiency and reduce risk in the development of drugs for therapeutic areas such as inflammation and respiratory disease.

Next-generation antibody platforms

    Feature

  • News Feature |

    Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as bispecifics and antibody-drug conjugates is now opening up new opportunities.

    • Rachel Brazil
  • Profiles

  • Advertisement Feature |

    F-star is developing a promising pipeline of immuno-oncology therapies with its innovative bispecific antibody technology, which is ideally suited to uncover novel combinatorial biology.

  • Advertisement Feature |

    Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.

  • Advertisement Feature |

    Celonic is a private Swiss biotech company specializing in the production of recombinant proteins in mammalian cell systems for use in any stage of drug development

  • Advertisement Feature |

    Making encoded library technology a viable alternative to HTS

Search

Quick links